There are few real-world data regarding the effects of SGLT2 inhibitors in this specific population of patients with CKD stages 3-5 who receive ACEIs/ARBs and participate in pre-ESRD programs in Taiwan 32. Here, SLC5A2 is linked to chronic kidney disease.